Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1083

1.

Designer Benzodiazepines: A Review of Published Data and Public Health Significance.

Greenblatt HK, Greenblatt DJ.

Clin Pharmacol Drug Dev. 2019 Feb 7. doi: 10.1002/cpdd.667. [Epub ahead of print] No abstract available.

PMID:
30730611
2.

Ketoconazole and Liver Injury: A Five-Year Update.

Greenblatt DJ, Mikus G.

Clin Pharmacol Drug Dev. 2019 Jan;8(1):6-8. doi: 10.1002/cpdd.652. No abstract available.

PMID:
30599463
3.

Resveratrol glucuronidation in vitro: potential implications of inhibition by probenecid.

Matin B, Sherbini AA, Alam N, Harmatz JS, Greenblatt DJ.

J Pharm Pharmacol. 2019 Mar;71(3):371-378. doi: 10.1111/jphp.13037. Epub 2018 Nov 12.

PMID:
30417385
4.

Effect of Rifampin-Isoniazid-Containing Antituberculosis Therapy on Efavirenz Pharmacokinetics in HIV-Infected Children 3 to 14 Years Old.

Kwara A, Yang H, Antwi S, Enimil A, Gillani FS, Dompreh A, Ortsin A, Opoku T, Bosomtwe D, Sarfo A, Wiesner L, Norman J, Alghamdi WA, Langaee T, Peloquin CA, Court MH, Greenblatt DJ.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01657-18. doi: 10.1128/AAC.01657-18. Print 2019 Jan.

5.

Is There Always a Right or Wrong?: Comments on the FDA Warnings About Triptans and the Serotonin Syndrome.

Shader RI, Greenblatt DJ.

J Clin Psychopharmacol. 2018 Dec;38(6):545-546. doi: 10.1097/JCP.0000000000000965. No abstract available.

PMID:
30303862
6.

Therapeutic Drug Monitoring of Antidepressants.

Fiaturi N, Greenblatt DJ.

Handb Exp Pharmacol. 2018 Sep 8. doi: 10.1007/164_2018_161. [Epub ahead of print]

PMID:
30194543
7.

The Prescription of Benzodiazepines for Panic Disorder: Time for an Evidence-Based Educational Approach.

Nardi AE, Cosci F, Balon R, Weintraub SJ, Freire RC, Krystal JH, Roth T, Silberman EK, Sonino N, Fava GA, Starcevic V, Dubovsky SL, Salzman C, Rickels K, Greenblatt DJ, Shader RI, Chouinard G; International Task Force on Benzodiazepines.

J Clin Psychopharmacol. 2018 Aug;38(4):283-285. doi: 10.1097/JCP.0000000000000908. No abstract available.

PMID:
29912790
8.

Sustained Impairment of Lurasidone Clearance After Discontinuation of Posaconazole: Impact of Obesity, and Implications for Patient Safety.

Greenblatt DJ, Harmatz JS, Ryan MJ, Chow CR.

J Clin Psychopharmacol. 2018 Aug;38(4):289-295. doi: 10.1097/JCP.0000000000000892.

PMID:
29851709
9.

International Task Force on Benzodiazepines.

Balon R, Chouinard G, Cosci F, Dubovsky SL, Fava GA, Freire RC, Greenblatt DJ, Krystal JH, Nardi AE, Rickels K, Roth T, Salzman C, Shader R, Silberman EK, Sonino N, Starcevic V, Weintraub SJ.

Psychother Psychosom. 2018;87(4):193-194. doi: 10.1159/000489538. Epub 2018 May 22. No abstract available.

10.

Persistence of a Posaconazole-Mediated Drug-Drug Interaction With Ranolazine After Cessation of Posaconazole Administration: Impact of Obesity and Implications for Patient Safety.

Chow CR, Harmatz JS, Ryan MJ, Greenblatt DJ.

J Clin Pharmacol. 2018 Nov;58(11):1436-1442. doi: 10.1002/jcph.1257. Epub 2018 May 11.

PMID:
29749631
11.

Opportunistic Journals in the Clinical Pharmacology Space: A Policy Statement From the Publications and Public Policy Committees of the American College of Clinical Pharmacology.

Greenblatt DJ, Bertino JS Jr.

J Clin Pharmacol. 2018 May;58(5):567-571. doi: 10.1002/jcph.1130. No abstract available.

PMID:
29677401
12.

Opportunistic Journals in the Clinical Pharmacology Space: A Policy Statement From the Publications and Public Policy Committees of the American College of Clinical Pharmacology.

Greenblatt DJ, Bertino JS Jr.

Clin Pharmacol Drug Dev. 2018 May;7(4):353-357. doi: 10.1002/cpdd.466. No abstract available.

PMID:
29677400
13.

Vortioxetine Disposition in Obesity: Potential Implications for Patient Safety.

Greenblatt DJ, Harmatz JS, Chow CR.

J Clin Psychopharmacol. 2018 Jun;38(3):172-179. doi: 10.1097/JCP.0000000000000861.

PMID:
29596146
14.

Gabapentin and Pregabalin for the Treatment of Anxiety Disorders.

Greenblatt HK, Greenblatt DJ.

Clin Pharmacol Drug Dev. 2018 Mar;7(3):228-232. doi: 10.1002/cpdd.446. No abstract available.

PMID:
29579375
15.

Inhibitory effects of sulfonylureas and non-steroidal anti-inflammatory drugs on in vitro metabolism of canagliflozin in human liver microsomes.

Algeelani S, Alkhelb D, Greenblatt DJ.

Biopharm Drug Dispos. 2018 Mar;39(3):135-142. doi: 10.1002/bdd.2120. Epub 2018 Feb 22.

PMID:
29319909
16.

Opioid Prescribing: What Are the Numbers?

Greenblatt DJ.

Clin Pharmacol Drug Dev. 2018 Jan;7(1):6-8. doi: 10.1002/cpdd.430. No abstract available.

PMID:
29276940
17.

Update on Psychotropic Drug Prescribing in the United States: 2014-2015.

Greenblatt DJ, Harmatz JS, Shader RI.

J Clin Psychopharmacol. 2018 Feb;38(1):1-4. doi: 10.1097/JCP.0000000000000831. No abstract available.

PMID:
29215384
18.

Effects of Flibanserin on the Pharmacokinetics of a Combined Ethinylestradiol/Levonorgestrel Oral Contraceptive in Healthy Premenopausal Women: A Randomized Crossover Study.

Johnson-Agbakwu C, Brown L, Yuan J, Kissling R, Greenblatt DJ.

Clin Ther. 2018 Jan;40(1):64-73. doi: 10.1016/j.clinthera.2017.08.021. Epub 2017 Dec 2.

19.

Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection.

Greenblatt DJ, Patel M, Harmatz JS, Nicholson WT, Rubino CM, Chow CR.

J Clin Pharmacol. 2018 Apr;58(4):533-540. doi: 10.1002/jcph.1040. Epub 2017 Nov 30.

PMID:
29194698
20.

Mechanism of in-vitro inhibition of UGT1A1 by paritaprevir.

Alam N, Angeli MG, Greenblatt DJ.

J Pharm Pharmacol. 2017 Dec;69(12):1794-1801. doi: 10.1111/jphp.12821. Epub 2017 Oct 9.

PMID:
28990653
21.

Inhibition of human cytochromes P450 in vitro by ritonavir and cobicistat.

Hossain MA, Tran T, Chen T, Mikus G, Greenblatt DJ.

J Pharm Pharmacol. 2017 Dec;69(12):1786-1793. doi: 10.1111/jphp.12820. Epub 2017 Sep 29.

PMID:
28960344
22.

In vitro inhibition of human UGT isoforms by ritonavir and cobicistat.

Algeelani S, Alam N, Hossain MA, Mikus G, Greenblatt DJ.

Xenobiotica. 2018 Aug;48(8):764-769. doi: 10.1080/00498254.2017.1370655. Epub 2017 Sep 11.

PMID:
28891378
23.

Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies.

Cao L, Kwara A, Greenblatt DJ.

J Pharm Pharmacol. 2017 Dec;69(12):1762-1772. doi: 10.1111/jphp.12812. Epub 2017 Sep 5.

24.

Recent Recall of a Generic Form of Extended-Release Paliperidone.

Shader RI, Greenblatt DJ.

J Clin Psychopharmacol. 2017 Oct;37(5):493-494. doi: 10.1097/JCP.0000000000000765. No abstract available.

PMID:
28786829
25.

Race, Gender, and Genetic Polymorphism Contribute to Variability in Acetaminophen Pharmacokinetics, Metabolism, and Protein-Adduct Concentrations in Healthy African-American and European-American Volunteers.

Court MH, Zhu Z, Masse G, Duan SX, James LP, Harmatz JS, Greenblatt DJ.

J Pharmacol Exp Ther. 2017 Sep;362(3):431-440. doi: 10.1124/jpet.117.242107. Epub 2017 Jun 29.

26.

Inhibitory Effects of Selected Antituberculosis Drugs on Common Human Hepatic Cytochrome P450 and UDP-glucuronosyltransferase Enzymes.

Cao L, Greenblatt DJ, Kwara A.

Drug Metab Dispos. 2017 Sep;45(9):1035-1043. doi: 10.1124/dmd.117.076034. Epub 2017 Jun 29.

27.

The Impact Non-Factor.

Greenblatt DJ, Shader RI.

J Clin Psychopharmacol. 2017 Aug;37(4):389-390. doi: 10.1097/JCP.0000000000000743. No abstract available.

PMID:
28609306
28.

The Journal of Clinical Pharmacology, Clinical Pharmacology in Drug Development, and the Impact Factor.

Bertino JS Jr, Greenblatt DJ.

Clin Pharmacol Drug Dev. 2017 May;6(3):218-219. doi: 10.1002/cpdd.359. No abstract available.

PMID:
28475820
29.

The Journal of Clinical Pharmacology, Clinical Pharmacology in Drug Development, and the Impact Factor.

Bertino JS Jr, Greenblatt DJ.

J Clin Pharmacol. 2017 May;57(5):545-546. doi: 10.1002/jcph.909. No abstract available.

PMID:
28409839
30.

Mechanisms and Consequences of Drug-Drug Interactions.

Greenblatt DJ.

Clin Pharmacol Drug Dev. 2017 Mar;6(2):118-124. doi: 10.1002/cpdd.339.

PMID:
28263467
31.

Pharmacokinetics cannot explain the increased effective dose requirement for morphine and midazolam in rats during their extended administration alone or in combination.

Schaller SJ, Alam SM, Mao J, Zhao Y, Blobner M, Greenblatt DJ, Martyn JA.

J Pharm Pharmacol. 2017 Jan;69(1):82-88. doi: 10.1111/jphp.12663. Epub 2016 Nov 28.

PMID:
27891611
32.

Clinical Pharmacology in Drug Development: Five Years in the Books.

Greenblatt DJ.

Clin Pharmacol Drug Dev. 2016 Nov;5(6):432-434. doi: 10.1002/cpdd.322. No abstract available.

PMID:
27870478
33.

Antidepressant-Associated Hyponatremia in the Elderly.

Greenblatt HK, Greenblatt DJ.

J Clin Psychopharmacol. 2016 Dec;36(6):545-549. Review. No abstract available.

PMID:
27755157
34.

Elements of a Good Scientific Paper.

Shader RI, Greenblatt DJ.

J Clin Psychopharmacol. 2016 Dec;36(6):539-541. No abstract available.

PMID:
27753727
35.

Stereo-Psychopharmacology: The Case of Citalopram and Escitalopram.

Ng I, Greenblatt HK, Greenblatt DJ.

Clin Pharmacol Drug Dev. 2016 Sep;5(5):331-5. doi: 10.1002/cpdd.293. No abstract available.

PMID:
27452501
36.

Body Size Changes Among National Collegiate Athletic Association New England Division III Football Players, 1956-2014: Comparison With Age-Matched Population Controls.

Elliott KR, Harmatz JS, Zhao Y, Greenblatt DJ.

J Athl Train. 2016 May;51(5):373-81. doi: 10.4085/1062-6050-51.5.14. Epub 2016 May 9.

37.

Clinical pharmacology in drug development - an update.

Greenblatt DJ.

Clin Pharmacol Drug Dev. 2015 Jul;4(4):243-4. doi: 10.1002/cpdd.211. No abstract available.

PMID:
27136903
38.

Meldonium (Mildronate): A Performance-Enhancing Drug?

Greenblatt HK, Greenblatt DJ.

Clin Pharmacol Drug Dev. 2016 May;5(3):167-9. doi: 10.1002/cpdd.264. Epub 2016 Apr 29. No abstract available.

PMID:
27128409
39.

A soft benzodiazepine.

Greenblatt DJ.

Clin Pharmacol Drug Dev. 2015 Mar;4(2):81-2. doi: 10.1002/cpdd.186. No abstract available.

PMID:
27128211
40.

Pharmacokinetics and Pharmacodynamics for Medical Students: A Proposed Course Outline.

Greenblatt DJ, Abourjaily PN.

J Clin Pharmacol. 2016 Oct;56(10):1180-95. doi: 10.1002/jcph.732. Epub 2016 May 9. No abstract available.

PMID:
26987681
41.

Use of Antipsychotics for the Treatment of Behavioral Symptoms of Dementia.

Greenblatt HK, Greenblatt DJ.

J Clin Pharmacol. 2016 Sep;56(9):1048-57. doi: 10.1002/jcph.731. Epub 2016 Apr 29. Review.

PMID:
26953213
42.

In Memoriam: David A. Flockhart, 1952-2015.

Greenblatt DJ, Abernethy DR.

J Clin Pharmacol. 2016 Apr;56(4):509-10. doi: 10.1002/jcph.726. Epub 2016 Feb 26. No abstract available.

PMID:
26919538
43.

A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression.

Weiss MD, Macklin EA, Simmons Z, Knox AS, Greenblatt DJ, Atassi N, Graves M, Parziale N, Salameh JS, Quinn C, Brown RH Jr, Distad JB, Trivedi J, Shefner JM, Barohn RJ, Pestronk A, Swenson A, Cudkowicz ME; Mexiletine ALS Study Group.

Neurology. 2016 Apr 19;86(16):1474-81. doi: 10.1212/WNL.0000000000002507. Epub 2016 Feb 24.

44.

Ketoconazole-Associated Liver Injury in Drug-Drug Interaction Studies in Healthy Volunteers.

Banankhah PS, Garnick KA, Greenblatt DJ.

J Clin Pharmacol. 2016 Oct;56(10):1196-202. doi: 10.1002/jcph.711. Epub 2016 Feb 29. Review.

PMID:
26829173
45.

Preclinical Rodent Toxicity Studies for Long Term Use of Ceftriaxone.

Ratti E, Berry JD, Greenblatt DJ, Loci L, Ellrodt AS, Shefner JM, Cudkowicz ME.

Toxicol Rep. 2015;2:1396-1403.

46.

Inhibition of 2-methoxyestradiol glucuronidation by probenecid.

Qian Y, Sherbini A, Matin B, Zhao Y, Castellot J, Greenblatt DJ.

J Pharm Pharmacol. 2015 Nov;67(11):1585-92. doi: 10.1111/jphp.12462. Epub 2015 Aug 14.

PMID:
26272356
47.

Evidence-based choice of ritonavir as index CYP3A inhibitor in drug-drug interaction studies.

Greenblatt DJ.

J Clin Pharmacol. 2016 Feb;56(2):152-6. doi: 10.1002/jcph.609. Epub 2015 Oct 9. No abstract available.

PMID:
26239522
48.

The Pharmacovigilance Syndrome.

Greenblatt DJ.

J Clin Psychopharmacol. 2015 Aug;35(4):361-3. doi: 10.1097/JCP.0000000000000367. No abstract available.

PMID:
26066340
49.

Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies.

Greenblatt DJ, Harmatz JS.

Br J Clin Pharmacol. 2015 Sep;80(3):342-50. doi: 10.1111/bcp.12668. Epub 2015 Jun 1. Review.

50.

American College of Clinical Pharmacology commentary on the Strategic Plan 2010-2014 Progress Report from the Office of Dietary Supplements, National Institutes of Health.

Greenblatt DJ, Peter RM; American College of Clinical Pharmacology.

J Clin Pharmacol. 2015 Jul;55(7):723-4. doi: 10.1002/jcph.517. Epub 2015 May 13. No abstract available.

PMID:
25882480

Supplemental Content

Loading ...
Support Center